Clinical Significance of Extreme Left Atrial Enlargement in Atrial Functional Mitral Regurgitation

Highlights

  • The majority of patients with ≥ moderate atrial functional mitral regurgitation (AFMR) had a left atrium volume index (LAVI) 50 to 99 ml/m 2.

  • Excessive left atrium enlargement with LAVI ≥ 150 ml/m 2 was present in 13% of patients with ≥ moderate AFMR.

  • Excessive left atrium enlargement was associated with severe mitral regurgitation and presence of symptoms.

  • LAVI ≥ 150 ml/m 2 was associated with worse outcomes in patients with ≥ moderate AFMR.

The left atrium (LA) size varies in patients with atrial functional mitral regurgitation (AFMR) and its clinical impact remains unclear. This study aimed to assess the distribution of LA volume index (LAVI) and the impact of LAVI on clinical outcomes in a large cohort of patients with ≥ moderate AFMR. Patients with AFMR diagnosed by transthoracic echocardiography in 2019 were retrospectively enrolled from the REVEAL-AFMR registry. The endpoint was a composite of cardiovascular death and heart failure hospitalization, compared across the LAVI groups. Of the 877 patients (age 78 ± 9 years, 45% male, 81% with atrial fibrillation), the median LAVI was 75 ml/m 2. LAVIs of < 50, 50 to 99, 100 to 149, 150 to 199, and ≥ 200 ml/m 2 were observed in 14%, 55%, 18%, 7%, and 6%, respectively. The prevalence of severe MR increased across these LAVI groups (10%, 19%, 38%, 62%, and 66%; p <0.01 for trend), and the prevalence of symptoms also worsened accordingly (56%, 61%, 62%, 82%, and 96%; p <0.01 for trend). During the median follow up of 2.9 years, LAVIs ≥ 200 and 150 to 199 ml/m 2 were associated with lower event-free survival compared with LAVI < 50 ml/m 2. LAVI ≥ 150 ml/m 2 was associated with the adverse event (adjusted hazard ratio 2.14; 95% CI, 1.30 to 3.52; p <0.01), notably independent of severe mitral regurgitation (MR) and atrial fibrillation. In conclusion, larger LA was associated with severe MR and symptoms in patients with AFMR. Extremely enlarged LA with LAVI ≥ 150 ml/m 2 was observed in 13% and associated with worse outcomes independent of MR severity and atrial fibrillation.

Central Illustration: Legend

Atrial functional mitral regurgitation (AFMR), which can occur in patients with left atrial (LA) and mitral annular enlargement mainly associated with atrial fibrillation or heart failure (HF) with a preserved ejection fraction, is a more recently recognized condition. ,,, As LA size is affected by atrial fibrillation and pressure or volume overload resulting from HF or valve heart disease, the LA is typically enlarged in patients with AFMR ; however, the degree of LA enlargement varies substantially among patients. Although excessive LA enlargement, referred to as giant LA, has occasionally been reported in patients with rheumatic mitral valve disease or prosthetic mitral valves, ,, it can also be observed in patients with AFMR.

Excessive LA enlargement may contribute to presence of symptoms and worse prognosis in patients with AFMR. It can induce respiratory dysfunction by compressing the left main bronchus or the middle and lower lobes of the right lung or hemodynamic disturbances by compressing the posterobasal portion of the left ventricular (LV) wall toward the interventricular septum. ,, LA volume index (LAVI) and left atrium diameter (LAD) have been a marker of high mortality or cardiovascular events in the normal population or in various cardiac conditions, such as atrial fibrillation, HF, or degenerative mitral regurgitation (MR). ,,,,, However, the definition, clinical manifestations, and prognostic impact of excessive LA enlargement remain poorly understood. Thus, this study aimed to (1) investigate the distribution of LAVI in patients with AFMR, (2) assess the impact of LAVI on clinical outcomes, and (3) delineate the risk factors for excessive LA enlargement.

Methods

From the REVEAL-AFMR registry, which consists of 26 participating institutions in Japan, 1,007 patients diagnosed with moderate or greater AFMR using transthoracic echocardiography (TTE) in 2019 were evaluated. The primary results and details of this cohort have been reported previously (+ PMID: 39513571). AFMR was defined with a prerequisite of preserved left ventricular (LV) function (ejection fraction ≥ 50%) and a dilated left atrium (LAVI ≥ 38 ml/m 2 for men, ≥ 41 ml/m 2 for women; if LAVI was not available, LA diameter [LAD] ≥ 40 mm for men, ≥ 37 mm for women; these values were based on the previous report of normal values in Japan). LA size was categorized into groups in 50 ml/m² increments, and their distribution and outcomes were compared. MR due to prolapse, flail leaflet or rheumatic changes was excluded by an echocardiologist specialist at each participating center. Patients with severe aortic stenosis or regurgitation and those with missing LAVI data were excluded to assess the impact of LAVI on clinical outcomes. Symptoms were assessed using the New York Heart Association (NYHA) functional classes. The presence of symptoms was defined as NYHA class II or higher and that of severe symptoms as NYHA class III or IV.

The study protocols complied with the Declaration of Helsinki and were approved by the Institutional Review Board of Juntendo University, Japan, with each participating center approving the execution of this study. The requirement for written informed consent was waived because of the retrospective observational and noninvasive nature of this study and opt-out consent was obtained. Study information, including the objectives, inclusion and exclusion criteria, primary outcomes, and names of the participating hospitals, was published in the publicly available University Hospital Information Network (UMIN-CTR; unique identifier: UMIN000046146) before the first patient was enrolled. Patients or members of the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

TTE

TTE was performed using commercially available state-of-the-art ultrasonography machines. Comprehensive TTE examinations were performed according to previously published guidelines. , Notably, LA volumes were assessed using the biplane disk summation method in apical 2- and 4-chamber views. As LAD is also a reference for diagnosing left atrial enlargement, we also evaluated LAD values corresponding to the LAVI measurements. LAD was measured as the anteroposterior linear dimension in the parasternal long-axis view. MR severity was evaluated with a multiparametric integrative approach. Valvular heart diseases including mitral regurgitation were considered significant if its grade was moderate or higher.

Clinical outcomes

The primary endpoints were cardiovascular mortality and hospitalization for HF. The first event during follow-up was used to determine event-free survival. Each hospital team obtained information on the possible occurrence and/or cause of death through electronic chart reviews and telephone interviews.

Statistical analyses

Continuous data are expressed as means ± standard deviations or medians (interquartile ranges), and categorical data are expressed as frequencies or percentages. Continuous variables were compared among the groups using 1-way analysis of variance (ANOVA) and repeated-measures ANOVA with Tukey’s post hoc test, whenever appropriate. Nominal variables were compared between groups using the chi-squared test. Trends in severe MR or symptoms across the LAVI grades were evaluated using the Cochran–Armitage trend test. Survival analysis was performed using the Kaplan–Meier method and log-rank test. In these analyzes, patients who died of no cardiovascular disease or who received MV intervention were censored at the event. The Cox proportional hazards model was used to identify independent predictors of cardiovascular mortality or hospitalization due to HF. The results are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Age, sex, body mass index, systolic blood pressure, NYHA functional class, previous history of HF hospitalization, serum hemoglobin levels, creatinine levels, and the European System for Cardiac Operative Risk Evaluation II scores were included in the multivariate model in accordance with other studies from this registry. To investigate the relationship between the LAVI and outcomes, a penalized spline model was used. The penalized spline allows for flexible modeling of nonlinear associations. The model included the LAVI as the predictor of interest, whereas the covariates of age, sex, and MR severity were included as adjustment variables. The penalized spline approach was selected to account for potential nonlinear relationships between the LAVI and outcome, ensuring a robust estimation of the association. A multivariate logistic regression analysis was performed to assess independent determinants for a large left atrium; variables with p <0.05 in univariate analysis or key clinical variables of interest were included as candidate variables for the multivariate model. The association between LAD and LAVI was studied using nonlinear regression. Receiver operating characteristic (ROC) curve analysis was performed to assess the accuracy of the LAD for the corresponding LAVI. The Youden index was used to determine the optimal cutoff value. Tests were 2-sided, and p <0.05 was considered statistically significant. Statistical analyzes were performed using JMP Pro 17 (SAS Institute, Cary, North Carolina). Time-dependent ROC curve analyzes for survival data were performed using EZR to evaluate the prognostic significance of LAVI (Omiya, Saitama, Japan). The Fine–Gray model was assessed to consider competing risk of death from no cardiovascular disease using EZR, which is for R. More precisely, it is a modified version of the R commander designed to add statistical functions frequently used in biostatistics.

Results

Of the 1,007 patients with moderate or greater AFMR, 52 with missing LAVI data and 78 with severe aortic stenosis or regurgitation were excluded. Of the remaining 877 patients, the mean age was 77 ± 9 years, 45% were men, atrial fibrillation was observed in 81%, and severe MR was observed in 27%. The median LAVI and LAD were 75 (58 to 110) ml/m 2 and 50 (44 to 57) mm, respectively. Among patients with AFMR, LAVIs < 50, 50 to 99, 100 to 149, 150 to 199, and ≥ 200 ml/m 2 were present in 119 (14%), 486 (55%), 162 (18%), 60 (7%), and 50 (6%), respectively. In these subgroups, severe MR was present in 11%, 19%, 38%, 62%, and 66% of the patients, respectively (p <0.01 for trend, Figure 1 ). Patient characteristics were compared among the 5 groups according to LAVI ( Table 1 ).

Figure 1

Distribution of left atrial volume index (LAVI) and mitral regurgitation (MR) severity. Among patients with ≥ moderate atrial functional MR, 55% had a LAVI of 50 to 99 ml/m 2. LAVI of 150 to 199 and ≥ 200 ml/m 2 were present in 7% and 6% of patients, respectively. Severe MRs were frequently observed in larger LAVI categories.

Table 1

Patient characteristics according to left atrial volume index (LAVI) grade

LAVI P
< 50 ml/m 2 N=119 50-99 ml/m 2 N=486 100-149 ml/m 2 N=162 150-199 ml/m 2 N=60 ≥ 200 ml/m 2 N=50
Age 74±11 77±9.1 78±7.9 78±7.6 78±8.7 <0.01
Men 49 (41) 197 (41) 84 (52) 29 (48) 33 (66) <0.01
Body surface area, m 2 1.54±0.19 1.54±0.19 1.55±0.21 1.55±0.18 1.62±0.20 0.084
Body mass index, kg/m 2 22±3.6 22±3.6 22±3.2 22±3.1 22±3.1 0.28
Atrial fibrillation 72 (60) 374 (77) 156 (96) 57 (95) 50 (100) <0.01
Permanent 36 (30) 262 (54) 150 (93) 56 (93) 49 (98)
Persistent 10 (8) 18 (4) 2 (1) 1 (2) 1 (2)
Paroxysmal 26 (22) 94 (19) 4 (2) 0 0
Smoking history [848/877] 43 (36) 156 (33) 55 (36) 20 (34) 22 (46) 0.50
Hypertension 97 (82) 412 (85) 135 (83) 51 (85) 45 (90) 0.71
Dyslipidemia 70 (59) 227 (47) 63 (39) 26 (43) 15 (30) <0.01
Diabetes 17 (14) 78 (16) 13 (8) 7 (12) 9 (18) 0.12
Coronary artery diseases 23 (19) 63 (13) 21 (13) 5 (8) 5 (10) 0.23
Peripheral artery diseases 4 (3) 23 (5) 11 (7) 3 (5) 1 (2) 0.59
Creatinine, mg/dL [859/877] 1.21±1.18 1.26±1.22 1.35±1.26 1.07±0.43 1.17±0.46 0.55
eGFR <30 ml/min/1.73m 2 [859/877] 8 (7) 23 (5) 8 (5) 3 (5) 4 (8) 0.81
Hemoglobin, g/dL [858/877] 12.3±2.1 11.9±2.0 11.7±1.9 11.1±1.9 11.7±2.0 <0.01
COPD 8 (7) 23 (5) 8 (5) 3 (5) 4 (9) 0.81
EuroScore II 2.71±0.39 3.41±0.19 3.78±0.34 3.80±0.55 3.13±0.60 0.28
Echocardiography
LV end-diastolic volume, ml 85±28 92±32 101±34 114±32 130±43 <0.01
LV end-systolic volume, ml 33±13 36±15 39±14 44±14 50±18 <0.01
LV ejection fraction, % 62±5.7 62±5.9 62±5.7 61±6.5 61±5.5 0.86
LV mass index, g/m 2 99±28 109±27 118±28 133±35 145±38 <0.01
Left atrial diameter, mm [875/877] 42±5.7 48±6.6 57±7.4 64±10 74±10 <0.01
LAVI, ml/m 2 44 [42-47] 69 [60-81] 115 [108-130] 162 [155-179] 250 [216-301] <0.01
E vel, cm/s 91±25 98±26 108±29 111±28 120±30 <0.01
E/e’ septal, [839/877] 15±6.2 16±6.5 15±6.2 16±6.8 15±5.8 0.12
Pulmonary artery systolic pressure, mmHg [731/877] 33±11 37±12 39±11 44±13 48±13 <0.01
Effective mitral regurgitant orifice, cm 2 [434/877] 0.23±0.083 0.24±0.077 0.28±0.10 0.33±0.12 0.35±0.17 <0.01
Aortic stenosis 2 (2) 23 (5) 3 (2) 1 (2) 0 0.12
Aortic regurgitation 7 (6) 32 (6) 8 (5) 2 (3) 3 (6) 0.85
Tricuspid regurgitation 30 (25) 213 (44) 91 (56) 44 (73) 37 (74) <0.01
Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Aug 8, 2026 | Posted by in CARDIOLOGY | Comments Off on Clinical Significance of Extreme Left Atrial Enlargement in Atrial Functional Mitral Regurgitation

Full access? Get Clinical Tree

Get Clinical Tree app for offline access